Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma

Fig. 4

a Cleaved caspase-7 and -9 were highly expressed with CKD-5 and sorafenib combination therapy. b CKD-5 and sorafenib monotherapy increased acetylated histone H3 levels, which were further increased by the combination treatment with CKD-5 and sorafenib. GPX4 expression was reduced by sorafenib treatment, and further decreased by the combination treatment of sorafenib and CKD-5. c mRNA expression of GPX4 was reduced by sorafenib treatment, which was further decreased by the combination treatment of sorafenib and CKD-5

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us